Hims & Hers generated $1.5 billion in revenue in 2024, reflecting a 69% year-over-year increase. See why I rate HIMS stock a ...

Hims & Hers Health's revenue grew 69% YoY, boosting its outlook. See why HIMS stock’s growth potential and high implied ...

Shares of Hims & Hers Health (NYSE: HIMS) sank 10.5% this week, according to data from S&P Global Market Intelligence. The ...

With the FDA shutting down its key revenue stream, Hims faces a tough road ahead--can it justify its valuation?

Hims & Hers Health, Inc.’s HIMS investors have been experiencing some short-term gains from the stock of late. Shares of the ...

RKLX, the Defiance Daily Target 2X Long RKLB ETF, seeks daily investment results that correspond to twice (200%) the daily percentage change of Rocket Lab, a company at the forefront of satellite ...

Of the 22 guru strategies we follow, HIMS rates highest using our Small-Cap Growth Investor model based on the published strategy of Motley Fool. This strategy looks for small cap growth stocks ...

Detailed price information for Hims & Hers Health Inc (HIMS-N) from The Globe and Mail including charting and trades.

Of the 22 guru strategies we follow, HIMS rates highest using our Small-Cap Growth Investor model based on the published strategy of Motley Fool. This strategy looks for small cap growth stocks ...

BofA analyst Allen Lutz reiterated an Underperform rating and $21 price target on Hims & Hers (HIMS) after Novo Nordisk (NVO) announced ...

Analysts are closely monitoring how these developments will affect Hims & Hers' business model and revenue projections. The ongoing legal proceedings and competitive dynamics present uncertainties ...

After years of weight loss drug shortages, the FDA is saying there’s now an adequate supply for most medications and they ...